Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRME files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrime Medicine reports Q1 2026 financial results and business highlights
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Prime Medicine issued a press release announcing its financial results and business highlights for the quarter ended March 31, 2026. The 8-K filing itself does not contain specific financial figures or operational updates.
Item 2.02 verify on EDGAR → -
high
The complete financial results and business updates are provided in the attached press release (Exhibit 99.1), which investors should review directly for details on revenue, expenses, cash position, and pipeline progress.
Exhibit 99.1 view on EDGAR →
Summary
Prime Medicine filed its quarterly earnings announcement for the first quarter of 2026, disclosing financial results and business highlights through a press release dated May 7, 2026. This is a standard quarterly reporting event for publicly traded biotechnology companies. The 8-K filing itself serves as a notification mechanism, with the substantive information contained in the attached press release exhibit.
Retail investors should review the full press release (Exhibit 99.1) to understand the company's cash runway, research and development progress on its gene editing programs, and any updates to clinical trial timelines. As a clinical-stage biotech company, Prime Medicine's quarterly disclosures typically focus on pipeline milestones, cash burn rate, and runway to key value-creating events. Watch for management commentary on upcoming clinical data readouts or regulatory interactions that could materially impact the company's valuation and development timeline.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results and business highlights through a press release. The 8-K itself does not contain the actual financial figures or business updates, which are provided in the attached press release exhibit. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Prime Medicine filed an 8-K attaching a press release dated May 7, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release, dated May 7, 2026, furnished herewith.
The 8-K attaches a press release dated May 7, 2026 as Exhibit 99.1. The filing body provides no detail on the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K alone. Investors should review Exhibit 99.1 directly to understand what was announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify